Clinical Trial Update: Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on clofarabine in relapsed or refractory T-cell or NK-cell non-Hodgkin's lymphoma (Phase 1/2) completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Natural Killer Cell Lymphoma
• Non-hodgkin Lymphoma
• T-cell Lymphoma

Drugs mentioned

• Clofarabine (clofarabine)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Leukemia, Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-05-17